NCT06421324 Personalised Health Recommendations to the General Population Through an Integrated AI Guided
| NCT ID | NCT06421324 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fundación para la Investigación del Hospital Clínico de Valencia |
| Condition | Gastric Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 450 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2026-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 450 participants in total. It began in 2024-06-01 with a primary completion date of 2026-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical study aims to be used to implement and validate the AIDA tool in two phases: * Phase 1: Risk stratification and personalised recommendations \& Model development * Phase 2: Mechanistic Model (Bioresource) development \& testing
Eligibility Criteria
Inclusion Criteria: * Subjects ≥ 18 years old with a diagnosis of GIM or previous or current H. pylori infection, to whom a gastroscopy is indicated within clinical care * Availability of a signed informed consent form to participate in the study Exclusion Criteria: * Patients to whom an endoscopy is performed for the follow-up of another illness such as oesophageal varices and/or for therapy such as endoscopic dilation, feeding tube placement or endoscopic resection * Subjects with a clinical diagnosis of gastric diseases other than GIM or GC * Patients who have received antimicrobials during the four weeks prior to the endoscopy * Patients who have received proton pump inhibitors and/or bismuth-based treatments at least two weeks prior to the endoscopy * Subjects for whom clinical data are not available: H. pylori status, eradication treatment, sex, age, tobacco smoking, and first-degree family history of gastric cancer * Subjects who lack the mental capacity to understand the nature and requirements of the study and who lack the ability to give informed consent
Contact & Investigator
Tania Fleitas, MD, PhD
PRINCIPAL INVESTIGATOR
Fundación para la Investigación del Hospital Clínico de Valencia
Frequently Asked Questions
Who can join the NCT06421324 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Gastric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06421324 currently recruiting?
Yes, NCT06421324 is actively recruiting participants. Contact the research team at amiralles@incliva.es for enrollment information.
Where is the NCT06421324 trial being conducted?
This trial is being conducted at Valencia, Spain.
Who is sponsoring the NCT06421324 clinical trial?
NCT06421324 is sponsored by Fundación para la Investigación del Hospital Clínico de Valencia. The principal investigator is Tania Fleitas, MD, PhD at Fundación para la Investigación del Hospital Clínico de Valencia. The trial plans to enroll 450 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.